Shots:
- The P-III PRIME2 trial evaluates Dupixent vs PBO with/out topical treatments in 160 adults with PN inadequately controlled with topical prescription therapies
- The trial met its 1EPs and all key 2EPs i.e., patients experienced a reduction in itch from baseline (37% vs 22%) @12wks.; reduction in itch from baseline (58% vs 20%) & patients achieved clear or almost clear skin (45% vs 16%) @24wks., greater improvements in measures of health-related QoL, skin pain & symptoms of anxiety & depression
- Additionally, safety results were consistent with the known safety profile of Dupixent in its approved indications, patients discontinued the treatment (3% & 30%) before 24wks.
Click here to read full press release/ article | Ref: PR Newswire | Image: The Print
The post Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis first appeared on PharmaShots.
